Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776964 | 0.84 | PDE5A (0.44) | TERTSMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL6450443 | 0.80 | PDE5A (0.49) | TERTSMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL6895181 | 0.79 | TERT (0.60) | TERTSMN1; SMN2MAPTPOLBPDE5A | |
| SCHEMBL6443282 | 0.77 | PDE5A (0.63) | TERTKMT2APDE5AALDH1A1 | |
| SCHEMBL1792 | 0.75 | TERT (0.65) | TERTMAPTKMT2AMEN1RAB9A | |
| SCHEMBL3579254 | 0.75 | PDE5A (0.46) | TERTMAPTPOLBKMT2AMEN1 | |
| SCHEMBL6772078 | 0.74 | MAPT (0.46) | SMN1; SMN2MAPTPOLBKMT2APKM | |
| SCHEMBL6447286 | 0.73 | MEN1 (0.39) | POLBKMT2AMEN1PDE5APKM | |
| SCHEMBL7960724 | 0.73 | TERT (0.65) | TERTSMN1; SMN2MAPTPDE5ARAB9A | |
| SCHEMBL8125815 | 0.73 | TERT (0.62) | TERTSMN1; SMN2MAPTKMT2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC | 2005-06-30 | — | — | US | disclosed |
| US-6809200-B2 | REACTING 5-ACETYL-N-(3-(AMINOCARBONYL)-5-ETHYL-1-(1-ETHYL-3-AZETIDINYL)-1H-PYRAZOL4 -YL)-2-ETHOXYNICOTINAMIDE, IN PRESENCE OF ALCOHOL OR ALKOXY COMPOUND AND A HYDROXIDE TRAPPING AGENT OR BASE | PFIZER INC. | 2004-10-26 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1176147-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | DPYD, HPRT1, SAMHD1 | TERT 385/4885SMN1; SMN2 2390/4885MAPT 4371/4885 |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | NOX4, VKORC1, DPYD | TERT 685/4885SMN1; SMN2 2682/4885MAPT 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.